Literature DB >> 22188636

Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Damien Gruson1, Frédéric Thys, Franck Verschuren.   

Abstract

Acute or destabilized heart failure (DHF) is characterized by new or worsening signs and symptoms of heart failure leading to admission to an emergency department. Biomarkers may support the diagnosis, the prognosis and the management of DHF patients. The aim of this review article is to discuss and evaluate the clinical usefulness of both recognized and potential new biomarker tests for use in heart failure.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22188636     DOI： 10.1007/bf03256468

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  131 in total

Review 1.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications.

Authors:  Robb D Kociol; Peter S Pang; Mihai Gheorghiade; Gregg C Fonarow; Christopher M O'Connor; G Michael Felker
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

Review 2.  Natriuretic peptides: update on Peptide release, bioactivity, and clinical use.

Authors:  A Mark Richards
Journal:  Hypertension       Date:  2007-04-23       Impact factor: 10.190

3.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage.

Authors:  Kristin N Luckenbill; Robert H Christenson; Allan S Jaffe; Johannes Mair; Jordi Ordonez-Llanos; Franca Pagani; Jillian Tate; Alan H B Wu; Ranka Ler; Fred S Apple
Journal:  Clin Chem       Date:  2008-03       Impact factor: 8.327

Review 4.  Rapid emergence of multimarker strategies in laboratory medicine.

Authors:  D Gruson; S Bodovitz
Journal:  Biomarkers       Date:  2010-06       Impact factor: 2.658

5.  Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study.

Authors:  Ronald Van Beneden; Olivier Gurné; Philippe L Selvais; Sylvie A Ahn; Annie R Robert; Jean-Marie Ketelslegers; Hubert G Pouleur; Michel F Rousseau
Journal:  J Card Fail       Date:  2004-12       Impact factor: 5.712

6.  Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Authors:  Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi
Journal:  Eur J Heart Fail       Date:  2010-06-05       Impact factor: 15.534

7.  More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors:  S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

8.  Use of myeloperoxidase for risk stratification in acute heart failure.

Authors:  Tobias Reichlin; Thenral Socrates; Patrick Egli; Mihael Potocki; Tobias Breidthardt; Nisha Arenja; Julia Meissner; Markus Noveanu; Mirjam Reiter; Raphael Twerenbold; Nora Schaub; Andreas Buser; Christian Mueller
Journal:  Clin Chem       Date:  2010-04-22       Impact factor: 8.327

9.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

10.  Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.

Authors:  Döne Onan; Luisa Pipolo; Eunice Yang; Ross D Hannan; Walter G Thomas
Journal:  Mol Endocrinol       Date:  2004-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.